Takeda completes TiGenix takeover

Aug 02, 2018

Takeda Pharmaceutical has acquired all outstanding ordinary shares and warrants of TiGenix.

Originally announced in January, the acquisition of the biopharmaceutical company that develops stem cell therapies was valuated at approximately $604 million. According to Takeda, the acquisition will further new treatments for patients with gastrointestinal disorders.

The TiGenix’s board unanimously supported Takeda’s acquisition agreement.

Read the full release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments